FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024106003> ?p ?o ?g. }

• W2024106003 abstract "Anemia is common among peritoneal dialysis (PD) patients, and most patients require erythropoiesis-stimulating agents (ESA) to maintain their hemoglobin concentrations within current guideline recommendations. Darbepoetin alfa is an ESA with a 3-fold longer half-life and greater in vivo biological activity than recombinant human erythropoietin, allowing less frequent dosing that may simplify anemia management in these patients, providing benefits to patients, care givers and health care providers. Clinical studies have confirmed the efficacy and safety of darbepoetin alfa administered at extended dosing intervals. However, there are limited data on the management of anemia with ESAs in PD patients in routine clinical practice. The aim of this multicenter observational study in European and Australian dialysis patients was to evaluate darbepoetin alfa administered once every 2 weeks (Q2W) in routine clinical practice for 12 months.PD patients ≥18 years old and converting to treatment with darbepoetin alfa Q2W were eligible for enrollment regardless of previous or current ESA use. Patients enrolled in the study were treated according to local usual clinical practice. Data were collected up to 6 months prior to and 12 months after conversion to darbepoetin alfa Q2W. The primary endpoint was hemoglobin concentration 12 months after conversion to darbepoetin alfa Q2W.Of the 741 eligible PD patients (mean age, 61 years; male, 57%), 640 (86%) completed the study. Mean hemoglobin concentration (g/dL) was 11.69 (95% CI, 11.53-11.86) 6 months before the conversion, 12.25 (95% CI, 12.13-12.38) at conversion, and 11.88 (95% CI, 11.74-12.02) 12 months after conversion to darbepoetin alfa Q2W. The weekly equivalent ESA dose (μg/wk) was a geometric mean of 25.24 (95% CI, 23.46-27.15) 6 months before conversion, 20.90 (95% CI, 19.13-22.83) immediately before conversion, 18.89 (95% CI, 18.13-19.68) at conversion and 19.04 (95% CI, 17.69-20.49) 12 months after conversion. Twelve months after conversion, 70% of patients were receiving darbepoetin alfa Q2W and 73% had hemoglobin concentrations >11.0 g/dL.In this large observational study, PD patients were able to maintain mean hemoglobin concentrations >11.0 g/dL after conversion to extended dosing of darbepoetin alfa Q2W, with no mean dose increase." @default.
• W2024106003 created "2016-06-24" @default.
• W2024106003 creator A5014917241 @default.
• W2024106003 creator A5039309895 @default.
• W2024106003 creator A5048650617 @default.
• W2024106003 creator A5049724333 @default.
• W2024106003 creator A5049941770 @default.
• W2024106003 creator A5060512020 @default.
• W2024106003 creator A5087190503 @default.
• W2024106003 date "2011-03-24" @default.
• W2024106003 modified "2023-10-16" @default.
• W2024106003 title "Extended dosing of darbepoetin alfa in peritoneal dialysis patients" @default.
• W2024106003 cites W1502849084 @default.
• W2024106003 cites W1715452167 @default.
• W2024106003 cites W1945929574 @default.
• W2024106003 cites W1978005541 @default.
• W2024106003 cites W1983331153 @default.
• W2024106003 cites W1989661749 @default.
• W2024106003 cites W2015555551 @default.
• W2024106003 cites W2067413782 @default.
• W2024106003 cites W2104416692 @default.
• W2024106003 cites W2114866267 @default.
• W2024106003 cites W2122598472 @default.
• W2024106003 cites W2155772167 @default.
• W2024106003 cites W2156553383 @default.
• W2024106003 cites W2185982964 @default.
• W2024106003 cites W65817400 @default.
• W2024106003 cites W3149132779 @default.
• W2024106003 doi "https://doi.org/10.1186/1471-2369-12-13" @default.
• W2024106003 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3072319" @default.
• W2024106003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21435267" @default.
• W2024106003 hasPublicationYear "2011" @default.
• W2024106003 type Work @default.
• W2024106003 sameAs 2024106003 @default.
• W2024106003 citedByCount "8" @default.
• W2024106003 countsByYear W20241060032012 @default.
• W2024106003 countsByYear W20241060032013 @default.
• W2024106003 countsByYear W20241060032014 @default.
• W2024106003 countsByYear W20241060032015 @default.
• W2024106003 countsByYear W20241060032016 @default.
• W2024106003 countsByYear W20241060032021 @default.
• W2024106003 crossrefType "journal-article" @default.
• W2024106003 hasAuthorship W2024106003A5014917241 @default.
• W2024106003 hasAuthorship W2024106003A5039309895 @default.
• W2024106003 hasAuthorship W2024106003A5048650617 @default.
• W2024106003 hasAuthorship W2024106003A5049724333 @default.
• W2024106003 hasAuthorship W2024106003A5049941770 @default.
• W2024106003 hasAuthorship W2024106003A5060512020 @default.
• W2024106003 hasAuthorship W2024106003A5087190503 @default.
• W2024106003 hasBestOaLocation W20241060031 @default.
• W2024106003 hasConcept C126322002 @default.
• W2024106003 hasConcept C142724271 @default.
• W2024106003 hasConcept C177713679 @default.
• W2024106003 hasConcept C203092338 @default.
• W2024106003 hasConcept C23131810 @default.
• W2024106003 hasConcept C2776164570 @default.
• W2024106003 hasConcept C2777288759 @default.
• W2024106003 hasConcept C2778248108 @default.
• W2024106003 hasConcept C2778534260 @default.
• W2024106003 hasConcept C2778917026 @default.
• W2024106003 hasConcept C2779056158 @default.
• W2024106003 hasConcept C2779978075 @default.
• W2024106003 hasConcept C2780182762 @default.
• W2024106003 hasConcept C2781404941 @default.
• W2024106003 hasConcept C535046627 @default.
• W2024106003 hasConcept C71924100 @default.
• W2024106003 hasConceptScore W2024106003C126322002 @default.
• W2024106003 hasConceptScore W2024106003C142724271 @default.
• W2024106003 hasConceptScore W2024106003C177713679 @default.
• W2024106003 hasConceptScore W2024106003C203092338 @default.
• W2024106003 hasConceptScore W2024106003C23131810 @default.
• W2024106003 hasConceptScore W2024106003C2776164570 @default.
• W2024106003 hasConceptScore W2024106003C2777288759 @default.
• W2024106003 hasConceptScore W2024106003C2778248108 @default.
• W2024106003 hasConceptScore W2024106003C2778534260 @default.
• W2024106003 hasConceptScore W2024106003C2778917026 @default.
• W2024106003 hasConceptScore W2024106003C2779056158 @default.
• W2024106003 hasConceptScore W2024106003C2779978075 @default.
• W2024106003 hasConceptScore W2024106003C2780182762 @default.
• W2024106003 hasConceptScore W2024106003C2781404941 @default.
• W2024106003 hasConceptScore W2024106003C535046627 @default.
• W2024106003 hasConceptScore W2024106003C71924100 @default.
• W2024106003 hasIssue "1" @default.
• W2024106003 hasLocation W20241060031 @default.
• W2024106003 hasLocation W20241060032 @default.
• W2024106003 hasLocation W20241060033 @default.
• W2024106003 hasLocation W20241060034 @default.
• W2024106003 hasLocation W20241060035 @default.
• W2024106003 hasOpenAccess W2024106003 @default.
• W2024106003 hasPrimaryLocation W20241060031 @default.
• W2024106003 hasRelatedWork W1590171812 @default.
• W2024106003 hasRelatedWork W1964706798 @default.
• W2024106003 hasRelatedWork W2007053419 @default.
• W2024106003 hasRelatedWork W2014074349 @default.
• W2024106003 hasRelatedWork W2084096604 @default.
• W2024106003 hasRelatedWork W2115592617 @default.
• W2024106003 hasRelatedWork W2154211481 @default.
• W2024106003 hasRelatedWork W2559607918 @default.
• W2024106003 hasRelatedWork W2903992936 @default.
• W2024106003 hasRelatedWork W4254879415 @default.

• next